SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Compounds institutional-market rollout and broader institutional push are the main focus, with traders linking the effort to potential growth in DeFi and tokenized assets. Some see it as a catalyst for COMP, while others remain frustrated that the token has lagged the wider crypto market.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have traders questioning how quickly the new aldosterone-inhibitor class can gain coverage and commercial traction, weighing on expectations for Mineralys planned launch. Some see the early sales as a normal reimbursement ramp for a chronic treatment, while others worry that a slow launch and competition could constrain lorundrostats sales potential.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

The FDAs accelerated approval of Inovios competing RRP treatment, Voceryq, has raised concerns about pressure on Precigens PAPZIMEOS sales. Traders debate the competitive threat against PAPZIMEOSs first-mover position and full approval, while some question Inovios ability to commercialize its drug and note its confirmatory-study requirement.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs reported payroll and payments integrationsincluding MoneyGram/Stellar, European deployments, and Robinhood Chain supportwhich traders see as potential drivers of adoption and ZBCN demand. Others question whether these partnerships will translate into meaningful token use, noting the coins weak or uneven price performance; some rumored connections remain unconfirmed.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook amid strong shipping demand and elevated freight rates is fueling expectations for stronger profits and dividends. Traders are also debating the uncertain Hapag-Lloyd takeover, with Israeli regulatory opposition raising the possibility the deal could be delayed or fail.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong earnings and growing natural-gas demand from AI data centers are driving bullish discussion, alongside Energy Transfers rising distributions. Many investors see its pipeline network as well positioned for that demand, while others are frustrated by muted unit-price action and cite interest rates, energy-market volatility, or the Texas Stock Exchange listing move as potential headwinds.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are drawing attention after its latest quarterly report, with traders focusing on subscriber growth, stronger gross margins and an upbeat profit outlook despite revenue and EPS misses. The sharp gain has surprised some investors, while skeptics point to rising expenses and the earnings shortfall.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has surged to a fresh 52-week high ahead of its Q3 earnings, with traders weighing expected BRIUMVI sales growth against unconfirmed buyout speculation. Heavy short-interest and call-option activity are also fueling short-squeeze chatter, though some investors argue the rally is positioning for earnings rather than a takeover.

dogwifhat (WIF) is a cryptocurrency and operates on the Solana platform. dogwifhat has a current supply of 998,836,666.706979. The last known price of dogwifhat is 0.1786325 USD and is up 7.56 over the last 24 hours. It is currently trading on 831 active market(s) with $51,931,928.88 traded over the last 24 hours. More information can be found at https://dogwifhat.us/.

dogwifhat

WIF is drawing attention for its prolonged sideways-to-lower trading and repeated selloffs that erase brief gains, with traders complaining about barcoding and weak performance. Some view the depressed range as an accumulation opportunity and anticipate a rebound, while others say demand is lacking and remain bearish.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms Q3 earnings beat and higher full-year outlook, alongside an expanded Amazon data-center partnership, are driving discussion. Bulls point to stronger results and growth potential, while skeptical traders argue the Amazon arrangement is conditional and see the post-news rally as overdone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

Axogen Q3 2026 Earnings Call Transcript

Axogen (NASDAQ:AXGN) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.read more...

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of +50.00% and +4.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GMED or AXGN: Which Is the Better Value Stock Right Now?

GMED vs. AXGN: Which Stock Is the Better Value Option?

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireVANCOUVER, BC, Oct. 3, 2026VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big...

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.read more...

• Reported GAAP EPS of $0.21 up 75.00% YoY
• Reported revenue of $75.83M up 26.22% YoY
• Axogen expects 2026 revenue of at least $290M, at least 29% growth, including at least $7M from BioCircuit; Axogen continues to expect gross margin of at least 73% and positive free cash flow.

Axogen's Q3 gross margin was 74.8% versus 76.6% a year earlier; nine-month net loss was -$18.77M, and disclosed risks include BioCircuit integration, supply-chain disruption, inflation, and hospital staffing.

Axogen's Q3 2026 revenue was $75.8M, up 26.2%; Avance coverage is approximately 96% of covered lives in the United States; Axogen decided to initiate Prostate market development beginning in 2027, and completed BioCircuit acquisition.

Axogen, Inc. engages in the development and marketing of surgical solutions for peripheral nerve regeneration and repair. It provides products and educational resources to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Avive Soft Tissue Membrane, AcroVal Neurosensory and Motor Testing System, and AxoTouch Two-Point Discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Axogen Inc.

AXGN Stock Rises After FDA Approves Nerve Repair Graft

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves.</li><li>It eliminates the need for a secondary nerve-harvest surgery, helping lower the risk of complications and aiding faster recovery.</li><li>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026.</li></ul><p>Shares of Axogen Inc. (AXGN) were up nearly 12% in Thursday’s opening trade after the company announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its nerve repair graft.</p><p>Axogen announced on late Wednesday that the FDA had approved its Biologics License Application for Avance, which is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.</p><p>Retail sentiment on Stocktwits around the&nbsp;<a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> soared, entering the ‘extremely bullish’ territory from ‘bullish’ a day ago, while message volumes increased to hover at ‘extremely high’ levels from ‘normal’ a day ago.</p><h2 class="st-heading-2">Why Is This Important?</h2><p>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves. It eliminates the need for a secondary nerve-harvesting surgery, helping reduce the risk of complications and enabling faster recovery.</p><p>“This milestone clarifies and strengthens our regulatory footing and confirms approval for use of Avance as an acceptable therapeutic option for treating peripheral nerve discontinuities in all of Axogen’s present nerve repair use cases,” said Michael Dale, CEO, Axogen.</p><h2 class="st-heading-2">When Will It Be Available?</h2><p>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026. Until then, the company will continue to offer Avance under the current tissue framework.</p><p>Axogen cautioned that since Avance is made from human donor tissue, there is a risk of transmitting infectious agents such as viruses.</p><h2 class="st-heading-2">Who Is Avance Aimed At?</h2><p>According to the company, Avance is intended for patients older than one month. These patients may have sensory nerve discontinuity of less than or equal to 25 millimeters.</p><p>For patients with sensory nerve continuity of more than 25 mm or those with mixed and motor nerve discontinuity, Avance has received accelerated approval, according to the company. It noted that continued approval is contingent upon confirmatory clinical trial results.</p><p><a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> is up 89% year-to-date and 110% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/robotics-stocks-surge-trump-executive-order-reports/cLIXDUjRE1r"><strong>iRobot, Richtech Robotics Stocks Surge As Trump Administration Reportedly Considers Executive Order To Accelerate Development</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.

Why Is AXGN Stock Rising Today?

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.15	--	--	N/A
Q3 '26	$0.13	$0.21	59.90%	BEAT
Q2 '26	$0.12	$0.12	-1.18%	MISSED
Q1 '26	$0.08	$0.07	-6.67%	MISSED
Q4 '25	$0.09	$0.07	-22.26%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXGN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings